McCarthy's
INTRODUCTION TO
HEALTH CARE DELIVERY
A Primer for Pharmacists
SIXTH EDITION

KIMBERLY S. PLAKE, PhD
Associate Professor
Department of Pharmacy Practice
Purdue University, College of Pharmacy

KENNETH W. SCHAFERMEYER, PhD
Professor and Director
Office of International Programs
St. Louis College of Pharmacy

ROBERT L. MCCARTHY, PhD
Professor and Dean Emeritus
School of Pharmacy
University of Connecticut

© Jones & Bartlett Learning, LLC. NOT FOR SALE OR DISTRIBUTION
Determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used. Insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious, but are used for instructional purposes only.

The authors, editor, and publisher have made every effort to provide accurate information. However, they are not responsible for errors, omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.
To my parents, Ralph and Joyce Illingworth, who instilled in me a love for learning.

—Kimberly S. Plake

To my wife, Donna, and my daughters, Julia and Valerie.

—Kenneth W. Schafermeyer

For my grandchildren, Patrick, Cole, Ellie, Oliver, Sawyer, and Charlie.

—Robert L. McCarthy
Contents

Preface .................................................. xvii
Contributors ........................................... xx

PART I—SOCIAL ASPECTS OF HEALTHCARE DELIVERY ................................. 1

Chapter 1—Healthcare Delivery in America: Historical and Policy Perspectives ...... 3
Jennifer L. Tebbe-Grossman

Case Scenario ........................................... 3
Learning Objectives ..................................... 4
Chapter Questions ....................................... 4
Introduction ............................................ 5
Paradoxes of the U.S. Healthcare System .................................................. 5
Health, Disease, and Health Practitioners in Colonial America ......................... 9
America in the 19th Century: The Healthcare Environment ............................... 10
Continuity and Change in Health Institutions and Professions ............................ 15
Health and Sickness Patterns in Historical Perspective .................................... 21
Health Policy Overview: 1900–1950 ................................................................. 25
Post–World War II Healthcare Changes ......................................................... 26
The Patient Protection and Affordable Care Act (PPACA) .................................. 28
Conclusion .................................................. 31
Questions for Further Discussion ............................................................... 31
Key Topics and Terms .................................................. 31
References .................................................. 32
Chapter 2—Healthcare Professionals and Interdisciplinary Care

Suvapun Bunniran and David J. McCaffrey III

Case Scenario .......................................................... 43
Learning Objectives .................................................. 43
Chapter Questions .................................................. 44
Introduction .................................................................. 44
Professions .................................................................. 44
Collaboration with Healthcare Providers ....................... 59
The Patient Centered Medical Home (PCMH) ................... 63
Defining Quality ........................................................... 64
Important Trends Affecting Healthcare Professionals ........ 69
Conclusion ................................................................. 73
Questions for Further Discussion ................................... 74
Key Topics and Terms ................................................ 74
References ............................................................... 75

Chapter 3—The Pharmacist and the Pharmacy Profession

Erin R. Holmes

Case Scenario .......................................................... 81
Learning Objectives .................................................. 81
Chapter Questions .................................................. 82
Introduction .................................................................. 82
Evolution of the Profession and Medication Use Systems .... 83
Expanding the Pharmacist’s Role ..................................... 86
Pharmacy Education and Training .................................. 92
Professional Pharmacy Organizations .............................. 94
Pharmacy Technicians .................................................. 97
Technology and the Pharmacy Profession ........................ 99
Pharmacy Workforce .................................................... 102
Conclusion ................................................................. 104
Questions for Further Discussion ................................... 105
Key Topics and Terms ................................................ 105
References ............................................................... 105
# Chapter 4—The Patient

*Kimberly S. Plake*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Scenario</td>
<td>109</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>110</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>110</td>
</tr>
<tr>
<td>Introduction</td>
<td>111</td>
</tr>
<tr>
<td>Definitions</td>
<td>111</td>
</tr>
<tr>
<td>Demographics</td>
<td>111</td>
</tr>
<tr>
<td>Treatment versus Prevention</td>
<td>112</td>
</tr>
<tr>
<td>Patients’ Expectations</td>
<td>113</td>
</tr>
<tr>
<td>Access to Health Information</td>
<td>113</td>
</tr>
<tr>
<td>Models of Care</td>
<td>114</td>
</tr>
<tr>
<td>Adherence</td>
<td>118</td>
</tr>
<tr>
<td>Cultural Influence on Health</td>
<td>121</td>
</tr>
<tr>
<td>Health Literacy</td>
<td>122</td>
</tr>
<tr>
<td>Health Behavior Models</td>
<td>123</td>
</tr>
<tr>
<td>Interventions</td>
<td>128</td>
</tr>
<tr>
<td>Conclusion</td>
<td>132</td>
</tr>
<tr>
<td>Questions for Further Discussion</td>
<td>132</td>
</tr>
<tr>
<td>Key Topics and Terms</td>
<td>132</td>
</tr>
<tr>
<td>References</td>
<td>132</td>
</tr>
</tbody>
</table>

# Chapter 5—Drug Use, Access, the Supply Chain, and the Role of the Pharmaceutical Industry

*Kyle D. Ross, Kimberly S. Plake, and Louis P. Garrison Jr.*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Scenario</td>
<td>137</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>138</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>138</td>
</tr>
<tr>
<td>Introduction</td>
<td>139</td>
</tr>
<tr>
<td>Drugs as Remedies, Poisons, or Magical Charms</td>
<td>139</td>
</tr>
<tr>
<td>Consumer Perspective on Drug Use.</td>
<td>140</td>
</tr>
<tr>
<td>Health Professionals’ Role in Drug Use.</td>
<td>142</td>
</tr>
<tr>
<td>Path of a Pharmaceutical from Idea to Prescription</td>
<td>143</td>
</tr>
</tbody>
</table>
Future Trends in the Pharmaceutical Sector ................................................. 153
Conclusion .................................................................................. 154
Questions for Further Discussion .................................................... 154
Key Topics and Terms .................................................................. 154
References ...................................................................................... 155

Chapter 6—Public Health ................................................................. 159
Ardis Hanson, Peter D. Hurd, and Bruce Lubotsky Levin
Case Scenario ................................................................................... 159
Learning Objectives ....................................................................... 160
Chapter Questions ......................................................................... 160
Introduction .................................................................................... 160
Historical Perspective ..................................................................... 161
Epidemiology .................................................................................. 162
Social Determinants of Health: Public Health Model ....................... 164
Health Disparities ........................................................................... 164
Changing Health Priorities ............................................................... 165
Models for Change ......................................................................... 168
Prevention ...................................................................................... 169
Pharmacy and Public Health ............................................................ 172
Conclusion and Implications for Pharmacy ........................................ 178
Questions for Further Discussion .................................................... 178
Key Topics and Terms .................................................................. 178
References ...................................................................................... 178

Chapter 7—Quality Improvement and Patient Safety ......................... 185
Kyle E. Hultgren and John B. Hertig
Case Scenario ................................................................................... 185
Learning Objectives ....................................................................... 186
Chapter Questions ......................................................................... 186
Introduction .................................................................................... 186
Theory of Human Error ................................................................... 187
Culture of Safety ............................................................................ 189
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication Use Process</td>
<td>190</td>
</tr>
<tr>
<td>Error Prone Drug Products</td>
<td>195</td>
</tr>
<tr>
<td>Root Cause Analysis and Failure Mode Effects Analysis</td>
<td>197</td>
</tr>
<tr>
<td>Continuous Quality Improvement</td>
<td>199</td>
</tr>
<tr>
<td>PDSA Cycle</td>
<td>200</td>
</tr>
<tr>
<td>Conclusion</td>
<td>206</td>
</tr>
<tr>
<td>Questions for Further Discussion</td>
<td>206</td>
</tr>
<tr>
<td>Key Topics and Terms</td>
<td>206</td>
</tr>
<tr>
<td>References</td>
<td>206</td>
</tr>
</tbody>
</table>

**PART II—ORGANIZATIONAL ASPECTS OF HEALTHCARE DELIVERY** ..... 209

**Chapter 8—Hospitals** ..... 211
*Catherine N. Otto and William W. McCloskey*

| Case Scenario                                                   | ..... 211 |
| Learning Objectives                                             | ..... 211 |
| Chapter Questions                                               | ..... 212 |
| Introduction                                                    | ..... 212 |
| Historical Perspective                                           | ..... 212 |
| Financing Hospital Care                                          | ..... 213 |
| Value-Based Purchasing                                           | ..... 214 |
| Hospital Characteristics                                         | ..... 214 |
| Hospital Management                                              | ..... 216 |
| American Hospital Association                                   | ..... 217 |
| Hospital Accreditation                                           | ..... 217 |
| The Future of Hospitals                                          | ..... 217 |
| The Pharmacist’s Role in a Hospital-Based Practice               | ..... 218 |
| Responsibilities of the Hospital Pharmacy                       | ..... 219 |
| Drug Distribution Systems                                        | ..... 220 |
| Centralized versus Decentralized Pharmacy Services               | ..... 221 |
| Intravenous Admixture Services                                   | ..... 222 |
| Nondistributive Pharmacy Services                                | ..... 222 |
| Adverse Drug Reaction Monitoring                                 | ..... 223 |
## PART III—ECONOMIC ASPECTS OF HEALTHCARE DELIVERY

### Chapter 14—Basic Economic Principles Affecting Health Care

*Kenneth W. Schafermeyer and Scott K. Griggs*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Scenario</td>
<td>349</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>349</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>350</td>
</tr>
<tr>
<td>Introduction</td>
<td>350</td>
</tr>
<tr>
<td>Economic Concepts in Individual Consumer Decision Making</td>
<td>351</td>
</tr>
<tr>
<td>Law of Diminishing Marginal Utility</td>
<td>352</td>
</tr>
<tr>
<td>The Law of Demand</td>
<td>353</td>
</tr>
<tr>
<td>The Law of Supply</td>
<td>358</td>
</tr>
<tr>
<td>Equilibrium Price</td>
<td>361</td>
</tr>
<tr>
<td>Elasticity of Demand</td>
<td>363</td>
</tr>
<tr>
<td>Determinants of Elasticity of Demand</td>
<td>366</td>
</tr>
<tr>
<td>Elasticity of Demand for Prescription Drugs</td>
<td>367</td>
</tr>
<tr>
<td>Conclusion</td>
<td>368</td>
</tr>
<tr>
<td>Questions for Further Discussion</td>
<td>368</td>
</tr>
<tr>
<td>Key Topics and Terms</td>
<td>369</td>
</tr>
</tbody>
</table>

### Chapter 15—Unique Aspects of Health Economics

*Kenneth W. Schafermeyer*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Scenario</td>
<td>371</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>371</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>372</td>
</tr>
<tr>
<td>Introduction</td>
<td>372</td>
</tr>
<tr>
<td>Perfectly Competitive Industries</td>
<td>372</td>
</tr>
<tr>
<td>Other Market Structures</td>
<td>373</td>
</tr>
<tr>
<td>The Healthcare Market</td>
<td>374</td>
</tr>
<tr>
<td>Improving Economic Performance of the Healthcare System</td>
<td>378</td>
</tr>
<tr>
<td>Conclusion</td>
<td>381</td>
</tr>
<tr>
<td>Questions for Further Discussion</td>
<td>381</td>
</tr>
<tr>
<td>Key Topics and Terms</td>
<td>381</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>382</td>
</tr>
<tr>
<td>Acknowledgment</td>
<td>382</td>
</tr>
<tr>
<td><strong>Chapter 16—Private Health Insurance</strong></td>
<td>383</td>
</tr>
<tr>
<td><em>Kenneth W. Schafermeyer and Taehwan Park</em></td>
<td></td>
</tr>
<tr>
<td>Case Scenario</td>
<td>383</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>383</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>384</td>
</tr>
<tr>
<td>Introduction</td>
<td>384</td>
</tr>
<tr>
<td>Iron Triangle of Health Care</td>
<td>385</td>
</tr>
<tr>
<td>History of Health Insurance</td>
<td>388</td>
</tr>
<tr>
<td>The Health Insurance Industry</td>
<td>391</td>
</tr>
<tr>
<td>Basic Principles and Strategies of Health Insurance</td>
<td>393</td>
</tr>
<tr>
<td>Administration of Prescription Drug Programs</td>
<td>398</td>
</tr>
<tr>
<td>Impact of Health Insurance on Pharmacy</td>
<td>402</td>
</tr>
<tr>
<td>Conclusion</td>
<td>403</td>
</tr>
<tr>
<td>Questions for Further Discussion</td>
<td></td>
</tr>
<tr>
<td>Key Topics and Terms</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td></td>
</tr>
<tr>
<td><strong>Chapter 17—Managed Health Care</strong></td>
<td>407</td>
</tr>
<tr>
<td><em>Kenneth W. Schafermeyer and Taehwan Park</em></td>
<td></td>
</tr>
<tr>
<td>Case Scenario</td>
<td>407</td>
</tr>
<tr>
<td>Learning Objectives</td>
<td>408</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>408</td>
</tr>
<tr>
<td>Introduction</td>
<td>408</td>
</tr>
<tr>
<td>The History of Managed Care</td>
<td>408</td>
</tr>
<tr>
<td>Types of Managed Care Organizations</td>
<td>409</td>
</tr>
<tr>
<td>Consumer-Driven Health Plans</td>
<td>413</td>
</tr>
<tr>
<td>Managing the Pharmacy Benefit</td>
<td>413</td>
</tr>
<tr>
<td>Ethical Issues in Managed Care</td>
<td>419</td>
</tr>
<tr>
<td>Quality in Managed Care</td>
<td>421</td>
</tr>
<tr>
<td>Creating Incentives</td>
<td>423</td>
</tr>
</tbody>
</table>
Questions for Further Discussion ........................................... 447
Key Topics and Terms ......................................................... 447
References .............................................................................. 447

Chapter 19—Pharmacoeconomics ........................................... 451
Scott K. Griggs, Craig I. Coleman, Taehwan Park, and Kenneth W. Schafermeyer

Case Scenario ........................................................................ 451
Learning Objectives .............................................................. 452
Chapter Questions ............................................................... 452
Introduction ........................................................................... 453
Comparing Pharmacoeconomic Methodologies ....................... 454
Steps for Conducting a Pharmacoeconomic Evaluation .............. 457
Pharmacoeconomic Methodologies ......................................... 467
Approaches to Conducting Pharmacoeconomic Studies ............... 474
Critical Appraisal of a Pharmacoeconomic Study ....................... 478
Conclusion ............................................................................ 478
Questions for Further Discussion ........................................... 478
Key Topics and Terms .......................................................... 479
References .............................................................................. 479

Chapter 20—International Healthcare Services ......................... 483
Ana C. Quiñones-Boex and Gregory A. Garcia

Case Scenario ........................................................................ 483
Learning Objectives .............................................................. 484
Chapter Questions ............................................................... 484
Introduction ........................................................................... 485
“Developed” and “Developing” Countries ................................ 485
Healthcare Delivery Systems in Selected Nations ....................... 489
International Healthcare Systems: Implications for the United States .......................................................... 505
Conclusion ............................................................................ 505
Questions for Further Discussion ........................................... 507
Key Topics and Terms .......................................................... 507
References .............................................................................. 507
# Chapter 21—Healthcare Reform

*Catherine N. Otto and Thomas E. Buckley*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Learning Objectives</td>
<td>513</td>
</tr>
<tr>
<td>Chapter Questions</td>
<td>513</td>
</tr>
<tr>
<td>Introduction</td>
<td>514</td>
</tr>
<tr>
<td>Identification of the Problem</td>
<td>514</td>
</tr>
<tr>
<td>An Issue of Access</td>
<td>515</td>
</tr>
<tr>
<td>The Best Health Care?</td>
<td>515</td>
</tr>
<tr>
<td>Demand versus Need</td>
<td>515</td>
</tr>
<tr>
<td>Healthcare Reform Efforts by the Federal Government</td>
<td>516</td>
</tr>
<tr>
<td>Healthcare Reform Efforts by the States</td>
<td>522</td>
</tr>
<tr>
<td>The Pharmacy Profession and Healthcare Reform: A Call for Action</td>
<td>528</td>
</tr>
<tr>
<td>Conclusion</td>
<td>529</td>
</tr>
<tr>
<td>Questions for Further Discussion</td>
<td>529</td>
</tr>
<tr>
<td>Key Topics and Terms</td>
<td>529</td>
</tr>
<tr>
<td>References</td>
<td>530</td>
</tr>
<tr>
<td>Glossary</td>
<td>533</td>
</tr>
<tr>
<td>Index</td>
<td>557</td>
</tr>
</tbody>
</table>
Preface

When the First Edition was published in 1998, Professor McCarthy hoped to meet a textbook need he felt was not adequately met. As an instructor who taught healthcare delivery, systems, and policy, he had long sought a book that provided an introduction to this rapidly evolving area, but that would do so from the perspective of pharmacy. In subsequent editions, we believe that we have been true to his original intent. Over the years, as we developed new editions, we tried to be responsive to the needs of our colleagues by adding, subtracting, and changing subject matter; by providing active learning exercises; and by developing online resources for instructors and students. Given the rapidly changing nature of healthcare delivery, we have also been committed to an aggressive revision schedule; this Sixth Edition is being published just 18 years after the First Edition.

The Sixth Edition includes several major revisions and chapter restructures to reflect the myriad changes that have occurred since the last edition 5 years ago. Chapter 7, Quality Improvement and Patient Safety, was added to reflect the growing importance in pharmacists’ work in this area. A new author has joined us and completely rewritten Chapter 13, Government Involvement in Health Care, using his many years of governmental relations experience to provide the reader a comprehensive, yet easy to follow, overview of how government impacts health care delivery in the United States each day, especially as we enter the sixth year of The Patient Protection and Affordable Care Act. Chapter 20, International Healthcare Services, again offers an opportunity for the reader to compare the wide array of health care delivery systems around the world, even as the United States opens a new chapter in its relationship with Cuba. We hope you will find the Sixth Edition of Introduction to Health Care Delivery: A Primer for Pharmacists achieves the goals of its forebears, but also enables instructors and students of healthcare delivery to consider, more fully, how healthcare services in general—and pharmacy services in particular—are delivered. Moreover, we hope that the text and its supplementary materials—including those provided online—will facilitate thoughtful discussions among students, faculty, and practitioners about not only how health care is delivered, but how the system might be improved for all those seeking care.

Kimberly S. Plake, West Lafayette, Indiana
Kenneth W. Schafermeyer, St. Louis, Missouri
Robert L. McCarthy, Storrs, Connecticut
2016
The sixth edition of *McCarthy’s Introduction to Health Care Delivery: A Primer for Pharmacists* includes new and updated information to reflect recent changes since the previous edition was published. This edition incorporates important updated material relating to the Affordable Care Act, Medicare and Medicaid, as well as an expanded section on pharmacist roles in public health, including immunizations, bioterrorism, and community health clinics. It includes information on post-graduate education, resources, and credentialing as well as scope of practice and related legislation and information on fellowships.

Information on improving patient safety, drug safety, and pharmaceutical industry and drug development is included in the new Chapter 7, *Quality Improvement and Patient Safety*. This chapter also covers new information on medication use processes including prescribing, monitoring, medication errors, and error prone drug products.

Chapter 13, *Government Involvement in Health Care*, was greatly rewritten to provide new information focusing on government’s perspective on the role of pharmacists and specific examples of state health insurance programs, including challenges of the Veterans Health Administration system. Information on global health care and developing countries was also added to this edition.

Recent developments and changes to online healthcare availability led to new information on E-commerce, internet pharmacy, and other technologies used in the health care field today. This edition also discusses electronic prescribing and electronic health records as well as Patient Safety and Clinical Pharmacy Services Collaborative (PSPC). Information on technologies used to improve safety and efficiency is included.

New resources were also added to Chapter 17, *Managed Health Care*, to discuss details on formularies, and drug utilization review, DUR, in greater detail.

New information to Chapter 19, *Pharmacoeconomics* was added to discuss consumer-driven healthcare and pharmacy reimbursement. This chapter also contains additional resources such as documents concerning a consolidated health economic evaluation reporting standards checklist, comparative effectiveness research, information on health technology assessment, and health-related quality of life.

Additionally, updated and new information was added about basic policy issues affecting health care today, pharmacy benefit managers, basic epidemiology, including discussion of incidence, prevalence, and risk, and information on the distribution process including wholesalers and prevention of counterfeits. New information on therapies used at home, as well as new funding for community health centers, patient-centered medical homes, and ambulatory care data was also added to this edition.
NEW TO THE SIXTH EDITION

Updated and enhanced content relating to:

- Expanded section regarding pharmacist roles
- Post-graduate education/resources
- Credentialing/resources
- Affordable Care Act
- Medicare and Medicaid
- Contraceptive views of health policy
- Government’s perspective on role of pharmacists (provider status)
- Examples of state health insurance programs
- Challenges of the VHA system
- E-commerce, internet pharmacy, and other technologies
- Interdisciplinary models of care
- Scope of practice and related legislation
- Sources of patient information
- Health and illness behavior
- Culture, health literacy, health behavior change and motivational interviewing
- Role of quality improvement in patient safety
- Drug safety
- Pharmaceutical industry and drug development
- Electronic prescribing and electronic health records
- Patient Safety and Clinical Pharmacy Services Collaborative (PSPC)
- Pharmacy benefit managers
- Basic policy issues affecting health care
- Connections between medication use systems and health care delivery models
- Demographics, including compression of morbidity
- Basic epidemiology, including discussions of incidence, prevalence, risk, etc.
- Distribution process, e.g., wholesalers
- Counterfeits and efforts to prevent occurrence
- Internet pharmacy
- DTC advertising
- E-Commerce
- Health care disparities
- Examples of pharmacist roles in public health (immunizations, bioterrorism, community health clinics, etc.)
- Continuous quality improvement
- Measures of quality
- Root cause analysis
- E-prescribing
- Technologies to improve safety and efficiencies
- Reimbursement
- The Joint Commission
- Multihospital systems, horizontal/vertical integration
- Fellowships
- Ambulatory care data
- LTC statistics
- New funding for community health centers
- New therapies used at home
- Economic principles affecting health care
- The uninsured
- Prescription drug plans
- Difference between private pay and Medicaid
- Expand discussion on HEDIS
- Supply-side and demand-side controls
- Consumer-driven healthcare
- PBMS, pharmacy reimbursement
- Details on formularies
- DUR
- Specialty pharmacies
- Cognitive reimbursement and MTM
- Transitions of Care
- Formulary review for expensive biotech drugs
- Health technology assessment
- Pharmacoeconomic methods
- Quality of life and health outcomes measurement
- Health education
- Developing countries
- Accountable care organizations (ACOS)
- Patient-centered medical homes (PCMS)
- Consumer driven health care
Contributors

Thomas E. Buckley, MPH, RPh
Associate Clinical Professor
University of Connecticut, School of Pharmacy
Storrs, Connecticut

Suvapun Bunniran, PhD
Principal Researcher
Comprehensive-Health-Insights | Humana
Louisville, Kentucky

Aleda M. H. Chen, PharmD, MS, PhD
Assistant Professor of Pharmacy Practice and Vice Chair, Pharmacy Practice/Social Sciences
Cedarville University, School of Pharmacy
Cedarville, Ohio

Craig I. Coleman, PharmD
Professor
University of Connecticut, School of Pharmacy
Storrs, Connecticut

Gregory A. Garcia, PharmD
PGY1 Pharmacy Resident
Alameda Health System Highland Hospital
Oakland, California

Louis P. Garrison Jr, PhD
Professor for Pharmaceutical Outcomes, Research, and Policy Program
Department of Pharmacy
Adjunct Professor
Departments of Global Health and Health Services
University of Washington, School of Pharmacy
Seattle, Washington

Scott K. Griggs, PharmD, PhD
Assistant Professor of Pharmacy Administration
St. Louis College of Pharmacy
St. Louis, Missouri

Ardis Hanson, PhD, MLS
Social and Behavioral Researcher; Research Coordinator
Dean’s Office
College of Behavioral and Community Sciences
University of South Florida
Tampa, Florida

John B. Hertig, PharmD, MS, CPPS
Associate Director
Center for Medication Safety Advancement
Purdue University College of Pharmacy
Fishers, Indiana

Erin R. Holmes, PharmD, PhD
Associate Professor of Pharmacy Administration
University of Mississippi
University, Mississippi

Kyle E. Hultgren, PharmD
Director
Center for Medication Safety Advancement
Purdue University College of Pharmacy
Fishers, Indiana

Peter D. Hurd, PhD
Professor, Pharmacy Administration and Chair
Department of Pharmaceutical and Administrative Sciences
Saint Louis College of Pharmacy
St. Louis, Missouri
Contributors

William G. Lang IV, MPH
Senior Policy Advisor
American Association of Colleges of Pharmacy
Alexandria, Virginia

Emily M. Laswell, PharmD, BCPS
Assistant Professor of Pharmacy Practice,
School of Pharmacy
Cedarville University
Cedarville, Ohio

Bruce Lubotsky Levin, DrPH, MPH
Associate Professor and Head
Behavioral Health Concentration
Department of Community and Family Health
College of Public Health
Associate Professor and Director
MS Degree in Child & Adolescent Behavioral
Health
College of Behavioral and Community Sciences
University of South Florida
Tampa, Florida

David J. McCaffrey III, BS, MS, PhD
Assistant Dean for Student Affairs
St. John Fisher College
School of Pharmacy
Rochester, New York

William W. McCloskey, BA, BS, PharmD
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and
Health Sciences
Boston, Massachusetts

Carol A. Ott, PharmD, BCPP
Clinical Associate Professor of Pharmacy
Practice
Clinical Pharmacy Specialist, Psychiatry
Eskenazi Health/Midtown Community Mental
Health
Purdue University College of Pharmacy
West Lafayette, Indiana

Catherine N. Otto, PhD, MBA
Dean
Health Occupations, Physical Education and
Business
Shoreline Community College
Shoreline, Washington

Taehwan Park, PhD
Assistant Professor of Pharmacy
Administration
St. Louis College of Pharmacy
St. Louis, Missouri

Ana C. Quiñones-Boex, PhD, MS
Associate Professor of Pharmacy
Administration
Midwestern University, Chicago College of
Pharmacy
Downers Grove, Illinois

Kyle D. Ross, PhD
Assistant Professor of Economics
Department of Economics
Kansas State University
Manhattan, Kansas

David M. Scott, MPH, PhD
Professor of Pharmacy Practice and Public
Health
North Dakota State University, College of
Health Professions
Fargo, North Dakota

Jennifer L. Tebbe-Grossman, PhD
Professor of Political Science and American
Studies
Massachusetts College of Pharmacy and
Health Sciences
Boston, Massachusetts
Reviewers

Susan dosReis, PhD
Associate Professor
Department of Pharmaceutical Health Services Research
University of Maryland School of Pharmacy
Baltimore, Maryland

David Gettman, BS Pharm, MBA, PhD
Professor
D’Youville College School of Pharmacy
Buffalo, New York

Laura Happe, PharmD, MPH
Director of Research and Publications,
Humana
Editor in Chief, Journal of Managed Care & Specialty Pharmacy
Louisville, Kentucky

Andrea Kjos, PharmD, PhD
Assistant Professor
Drake University College of Pharmacy and Health Sciences
Des Moines, Iowa

Isaac D. Montoya, PhD
Professor
University of Texas, Houston
Houston, Texas

Kam Nola, PharmD, MS
Vice-Chair, Pharmacy Practice and Associate Professor
Lipscomb University College of Pharmacy
Nashville, Tennessee

Roland A. Patry, DrPH
Professor and Chair
Department of Pharmacy Practice
Texas Tech School of Pharmacy
Amarillo, Texas

Tatjana Petrova, PhD
Assistant Professor
Chicago State University College of Pharmacy
Chicago, Illinois

John M. Polimeni, PhD
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York

Crescent Rowell, PharmD, PhD
Assistant Professor
Lipscomb University College of Pharmacy
Nashville, Tennessee

Justin Scholl, PharmD
Assistant Professor
Lake Erie College of Osteopathic Medicine School of Pharmacy
Erie, Pennsylvania

Patricia Shane, PhD, MPH
Professor
Touro University
Vallejo, California
Charles D. Shivley, PhD, RPh
Associate Professor, Pharmaceutical Sciences and Pharmacist-in-Charge, PC Community Care Pharmacies
Presbyterian College School of Pharmacy
Clinton, South Carolina

Walter Siganga, PhD
Professor
Southern Illinois University Edwardsville
School of Pharmacy
Edwardsville, Illinois

Karen L. Smith, MS, PhD, RPh
Assistant Professor
Regis University School of Pharmacy
Denver, Colorado

Michael A. Veronin, PhD, RPh
Associate Professor
Texas A&M University Health Science Center
Rangel College of Pharmacy
Kingsville, Texas

Tatiana Yero, PharmD, BCPP
Assistant Professor
Lake Erie College of Osteopathic Medicine
School of Pharmacy
Bradenton, Florida